



NDA 10-379/S-045

Jones Pharma Inc.
Attention: Nancy Cafmeyer
Director, Regulatory Affairs
1945 Craig Rd
St. Louis, MO 63146

Dear Ms. Cafmeyer:

Please refer to your supplemental new drug application dated January 22, 2001, received January 23, 2001, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Cytomel (liothyronine sodium) Tablets, 5 mcg, 25 mcg, and 50 mcg.

This "Changes Being Effected" supplemental new drug application provides for revised container labels to state that each tablet contains liothyronine sodium equivalent to a certain amount (5, 25, or 50 mcg) of liothyronine.

We have completed the review of this supplemental application and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the submitted final printed labeling (immediate container labels submitted January 22, 2001). Accordingly, the supplemental application is approved effective on the date of this letter.

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Steve McCort, Regulatory Project Manager, at (301) 827-6415.

Sincerely,

{See appended electronic signature page}

David G. Orloff, M.D.

Director

Division of Metabolic and Endocrine Drug Products

Office of Drug Evaluation II

Center for Drug Evaluation and Research

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

David Orloff
9/13/01 06:13:23 PM